Procter & Gamble Health Limited (NSE: PGHL) has recommended a final dividend of ₹45 per equity share for FY2025-26, as disclosed to the NSE on 26 May 2026. Combined with the interim dividend of ₹160 per share declared on 6 February 2026, the company's total dividend payout for FY26 stands at ₹205 per equity share. The board also submitted its financial results for the quarter ended 30 June 2026 to the exchange on 6 August 2026.

Dividend Details and Yield

The ₹45 final dividend follows an interim payout that itself included a one-time special component of ₹50 per share, bringing the regular interim dividend to ₹110 per share for FY26. With PGHL's stock price not available in the current data feed, a precise trailing dividend yield cannot be calculated at this time. Investors should note that the total declared payout of ₹205 per share represents a significant cash return relative to the company's face value of ₹10 per share, implying a payout multiple of 20.5 times face value.

Year-on-Year Comparison

In FY2024-25, PGHL paid a total dividend of ₹125 per share, comprising an interim dividend of ₹80 per share (declared 12 February 2025) and a final dividend of ₹45 per share (declared 29 May 2025). The FY26 total of ₹205 per share represents a 64% increase over the prior year's aggregate payout, driven primarily by the higher interim dividend that included the one-time special component of ₹50 per share.

Multi-Year Dividend Trend

A review of PGHL's dividend history over the past three fiscal years reveals a pattern of both regular distributions and periodic special payouts:

The data indicates that PGHL's base regular dividend, excluding special one-time components, has remained relatively stable. The elevated aggregate payouts in FY24 and FY26 were driven by extraordinary special dividends, suggesting the company periodically distributes surplus cash reserves to shareholders rather than maintaining a linear dividend growth trajectory.

Company Background

Procter & Gamble Health Limited is a subsidiary of the global P&G group and operates primarily in the consumer healthcare segment in India, with brands spanning vitamins, minerals, and supplements. The company is listed on both NSE and BSE and follows a dual-dividend structure with interim and final payouts each financial year.

What This Means for Investors

The ₹45 final dividend recommendation is subject to shareholder approval at the upcoming Annual General Meeting. Investors holding PGHL shares as of the record date will be eligible for this payout. The recurrence of a special dividend component in FY26, after a similar exercise in FY24, signals that the management continues to view periodic capital returns as a tool for optimising the balance sheet. The absence of a special payout in FY25's total of ₹125 per share underscores that such distributions are discretionary and not guaranteed annually. Investors should factor in the distinction between recurring and one-time dividend components when assessing the stock's sustainable income yield.